SUBSCRIBE
SUBSCRIBE
News   Drug Development

Synosia Therapeutics Announces Positive Interim Results for Potential First-in-Class Treatment for Parkinson’s Disease

February 1, 2010 | 
1 min read
Bookmark and Share

BASEL, Switzerland--(BUSINESS WIRE)--Synosia Therapeutics today announced interim positive data from a Phase IIa clinical study of an adenosine 2a (A2a) receptor antagonist (SYN115) in Parkinson’s disease.
Clinical research Phase 2 Europe
MORE ON THIS TOPIC
cloud with rain of coins on blue background. minimal concept of investment, success and cryptocurrencies. 3d rendering
Insights
Rethinking Biotech’s Valley of Death as Federal Grants and Family Offices Step In
March 4, 2026
 · 
3 min read
 · 
Jennifer Smith-Parker
IN PARTNERSHIP WITH MEDSIR
Webinar: The Future is Collaborative: Transforming Clinical Trials
March 3, 2026
 · 
1 min read
 · 
BioSpace Insights
Dream Birds Flying Away, the birds flying out of a bird an open cage, the birds released from a cage, freedom concept. birds set free vector illustration.
Gene therapy
Intellia’s CRISPR Gene Therapy Free To Move Forward After FDA Fully Lifts Hold
March 3, 2026
 · 
2 min read
 · 
Tristan Manalac
Man walking on a long wavy path with flag at the end, persistence, determination and ultimate business success - 3D Render
Rare disease
UniQure Eyes Phase 3 for Huntington’s Gene Therapy Despite Makary’s Apparent Criticism
March 2, 2026
 · 
3 min read
 · 
Heather McKenzie